Shariq Shamim: Are We Going to Start DOAC post TAVI not DAPT?
Shariq Shamim, Interventional Cardiologist at Bon Secours Harbour View Medical Center, shared JAMA Cardiology‘s post on X:
“Are we going to start DOAC post TAVI not DAPT?”
JAMA Cardiology shared a post on X about a recent article by Christopher S. Dodgson et al. published in JAMA, adding:
“Presented at ESC Congress from JAMA:
After Transcatheter Aortic Valve Implant, factor Xa inhibitor non–vitamin K antagonist oral anticoagulant monotherapy reduced hypoattenuated leaflet thickening vs acetylsalicylic acid monotherapy.”
Title: Anticoagulation Monotherapy vs Antiplatelet Monotherapy After Transcatheter Aortic Valve Implant: The ACASA-TAVI Randomized Clinical Trial
Authors: Christopher S. Dodgson, Jon Herstad, Sophie F. Kløve, Malin Flygel, Mehdi Akhavi, Sverre Høie, Jan Otto Beitnes, Christian H. Eek, Kaspar Broch, Céline Cunen, Lars Gullestad, Lars Aaberge, Ketil Lunde, Bjørn Bendz, Øyvind H. Lie
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 16, 2026, 16:22Shannon Farmer: Driving Patient Blood Management Forward in Australia and New Zealand
-
Oct 16, 2026, 16:01Obi Light Ogbonnia: The Greatest Reward Is Changing Lives, Not Winning Awards
-
Oct 16, 2026, 15:18Carmine Liberatore: Limited Accuracy of VTE Risk Scores in Multiple Myeloma
-
Oct 16, 2026, 14:55Alex Borstein and the Bleeding Phenotype of Hemophilia A Carriers
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A